Severe interstitial lung disease following treatment with certolizumab pegol: a case report

Lager, Jakob; Hilberg, Ole; Løkke, Anders; Bendstrup, Elisabeth

doi:10.1183/09059180.00002013

Cited by 22 publications

(10 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…No reports are describing the use of certolizumab or golimumab in the treatment of RA-ILD patients, but, on the contrary, a possible relationship between these drugs and new-onset or acute exacerbation (AE) of ILD has been described [100,[126][127][128][129]. In 2017, a post-marketing surveillance study from 2579 Japanese patients treated with certolizumab reported an event rate of ILD of 1.22 per 100 patient-year (Table 4 and Figure 1) [130].…”

Section: Golimumab and Certolizumabmentioning

confidence: 99%

Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows

Cassone

Manfredi

Vacchi

et al. 2020

JCM

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic and systemic inflammatory disease affecting 0.5–1% of the population worldwide. Interstitial lung disease (ILD) is a serious pulmonary complication of RA and it is responsible for 10–20% of mortality, with a mean survival of 5–8 years. However, nowadays there are no therapeutic recommendations for the treatment of RA-ILD. Therapeutic options for RA-ILD are complicated by the possible pulmonary toxicity of many disease modifying anti-rheumatic drugs (DMARDs) and by their unclear efficacy on pulmonary disease. Therefore, joint and lung involvement should be evaluated independently of each other for treatment purposes. On the other hand, some similarities between RA-ILD and idiopathic pulmonary fibrosis and the results of the recent INBIULD trial suggest a possible future role for antifibrotic agents. From this perspective, we review the current literature describing the pulmonary effects of drugs (immunosuppressants, conventional, biological and target synthetic DMARDs and antifibrotic agents) in patients with RA and ILD. In addition, we suggest a framework for the management of RA-ILD patients and outline a research agenda to fill the gaps in knowledge about this challenging patient cohort.

show abstract

Section: Golimumab and Certolizumabmentioning

confidence: 99%

Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows

Cassone

Manfredi

Vacchi

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…Reports of new-onset ILD have been described for all five TNF-α inhibitors currently approved for the treatment of rheumatoid arthritis [7,46,101,102]. Studies have reported sarcoid-like granulomatous disease, organising pneumonia and exacerbation of pre-existing ILD; however, most of these studies have been small and infection was not clearly ruled out [10,28,89].…”

Section: Tnf-α Inhibitorsmentioning

confidence: 99%

Rheumatoid arthritis-associated lung disease

et al. 2015

View full text Add to dashboard Cite

“…Small case series of patients with RA-ILD have shown that infliximab and etanercept could improve dyspnea and cough, as well as stabilize disease functional status (104–107). On the other hand, safety concerns have been raised for current TNF-α inhibitors infliximab (108–111), etanercept (112–116), adalimumab (117–121), golimumab (90), and certolizumab (37, 122, 123) considering reports for ILD exacerbation. Importantly, TNF- induced ILD could be rapidly progressive and even fatal, especially in patients with preexisting ILD (34, 124–127).…”

Section: Connective Tissue Disease-associated Interstitial Lung Diseamentioning

confidence: 99%

Biologic Treatments in Interstitial Lung Diseases

et al. 2019

View full text Add to dashboard Cite

Interstitial lung diseases (ILD) represent a group of heterogeneous parenchymal lung disorders with complex pathophysiology, characterized by different clinical and radiological patterns, ultimately leading to pulmonary fibrosis. A considerable proportion of these disease entities present with no effective treatment, as current therapeutic regimens only slow down disease progression, thus leaving patients, at best case, with considerable functional disability. Biologic therapies have emerged and are being investigated in patients with different forms of ILD. Unfortunately, their safety profile has raised many concerns, as evidence shows that they might cause or exacerbate ILD status in a subgroup of patients. This review article aims to summarize the current state of knowledge on their role in patients with ILD and highlight future perspectives.

show abstract

Severe interstitial lung disease following treatment with certolizumab pegol: a case report

Cited by 22 publications

References 5 publications

Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows

Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows

Rheumatoid arthritis-associated lung disease

Biologic Treatments in Interstitial Lung Diseases

Contact Info

Product

Resources

About